#USA #J.P. Morgan #IDEAYA Biosciences #South San Francisco #Precision Medicine

IDEAYA Biosciences to Participate in Key Healthcare Conference

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leader in precision medicine focused on oncology, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, set to take place on January 13, 2025. This event is anticipated to be a crucial platform for IDEAYA to share insights on their strategic plans for 2025 and provide updates on their clinical programs. The presentation will be led by Yujiro S. Hata, CEO of IDEAYA, who will engage in a Q&A session post-presentation with Anupam Rama, a Managing Director at J.P. Morgan.

2025 Corporate Guidance

During the conference, IDEAYA plans to present its corporate guidance for the upcoming year, emphasizing its robust financial health with approximately $1.2 billion in cash and equivalents as of September 30, 2024. This financial strength is expected to support the company’s operations through at least 2028, allowing them to continue their cutting-edge research and development in targeted therapies.

Key Clinical Programs

Among the highlights IDEAYA will discuss are advancements in its clinical programs, specifically:

• - Darovasertib: This potential first-in-class Phase 2/3 PKC inhibitor is aimed at treating Metastatic Uveal Melanoma (MUM) and Uveal Melanoma (UM). The company anticipates a readout for progression-free survival from a trial involving a combination of darovasertib and crizotinib in HLA-A2-negative MUM patients by the end of 2025, depending on patient enrollment and data maturity. As of January 6, 2025, more than 200 patients have already been enrolled in this study.

• - IDE397: This innovative MAT2A Inhibitor is currently in a Phase 1/2 study. The company plans to provide updates on its combination trial with Trodelvy® for MTAP-deletion urothelial cancer in 2025 and aims to initiate a combination study with IDE892 targeting non-small cell lung cancer (NSCLC) later in the year.

• - IDE849: Another promising candidate is IDE849 (SHR-4849), which targets Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NETs). Clinical updates are expected in 2025, showcasing its preclinical efficacy and patient case studies.

• - IDE161 and IDE705: Both of these programs aim to tackle different aspects of solid tumor treatment, with planned expansions and combination therapies also anticipated in 2025.

IDEAYA’s forward-looking statements aim to clarify the company's commitment to precision medicine and its dedication to leveraging molecular diagnostics for effective drug development. The company integrates a framework that combines biomarker identification with drug discovery to ensure their targeted therapies reach the patients most likely to benefit.

IDEAYA encourages interested parties to view its updated JPM 2025 corporate presentation available on their Investor Relations website, which outlines their strategic roadmap and anticipated developments in clinical trials.

The live audio webcast of IDEAYA’s session, including the Q&A, can be accessed through the IDEAYA website, with a recording available afterward for those who wish to catch up on the insights shared.

Conclusion

As IDEAYA Biosciences gears up for the J.P. Morgan Healthcare Conference, the anticipation around their innovative strategies and clinical advancements is palpable. By focusing on targeted therapies that align with precision medicine, IDEAYA continues to pave the way for new treatment options in oncology, helping to address the unmet needs of patients with various solid tumors.